Patents for Foamix’s Foam Technology Issued in New Zealand and South Africa

Ness Ziona, Israel, November 13, 2007– Foamix Ltd., a leading developer of topical foam products for dermatology, gynecology and skin-care, has been awarded a New Zealand patent and four South African patents related to the Company’s proprietary foam technology.

NZ Patent No. 540,166, entitled “Cosmetic and Pharmaceutical Foam”, one of the company’s basic technology platform patents, was granted on October 11, 2007. South African Patent No. ZA 2005/03298 with the same title was granted on August 30, 2006; ZA 2005/02180, titled “Penetrating Pharmaceutical Foam” was granted on June 28, 2006, and ZA 2005/02171 titled “Foam Carrier Containing Amphiphilic Copolymeric Gelling Agent” and ZA 2005/07017 titled “Cosmetic and Pharmaceutical Foam with Solid Matter” were both granted March 28, 2007.

“These new patents and our anticipated future grants worldwide define our serious intentions in this field,” stated Dr. Dov Tamarkin, Chief Executive Officer of Foamix. “Our versatile foam technologies enable the development of superior topical products, with enhanced functionality and ease-of-use, compared with traditional topical modalities. These patent grants are indicative of Foamix’s ongoing progress in solidifying its intellectual property domain worldwide, for the benefit of Foamix and its industrial partners.”

In addition to the above, Foamix holds 3 issued US patents and has 57 patents pending in the United States.

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a specialty pharmaceutical company focused on the development of topical foam products for prescription, OTC and cosmetic applications. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. We currently collaborate with 8 pharmaceutical companies on 10 projects in the development of proprietary dermatological and gynecological foam drugs; and we have our own in-house pipeline of dermatological and gynecological drugs in foam presentation.
The company’s development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing, preclinical and clinical studies.

For additional information please visit www.foamix.co.il.

Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il